Clinical trial
Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea
NCT01885000 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Patient-Reported Outcomes of Brimonidine Tartrate 0.5% Gel for Treatment of Severe Facial Erythema of Rosacea
- Lead sponsor
- Galderma R&D
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 1, 2013
- Completion date
- November 14, 2013
- Enrollment
- 92 (actual)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.